Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?
about
sameAs
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysisPlatelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysisResistance to antiplatelet drugs: current status and future researchBiological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteersAspirin and clopidogrel resistance: consideration and managementAntithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actionsRecent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems-765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia.Prognostic role of host cyclooxygenase and cytokine genotypes in a Caucasian cohort of patients with gastric adenocarcinomaEffect of common single nucleotide polymorphisms in COX-1 gene on related metabolic activity in diabetic patients treated with acetylsalicylic acidPharmGKB summary: very important pharmacogene information for PTGS2.The role of genetics in pre-eclampsia and potential pharmacogenomic interventions.Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery diseaseEffect of common single-nucleotide polymorphisms in acetylsalicylic acid metabolic pathway genes on platelet reactivity in patients with diabetes.Pharmacogenomics of platelet responsiveness to aspirin.Advances in our understanding of "resistance" to antiplatelet agents for prevention of ischemic strokeAspirin resistance: biological and clinical implications.Pharmacogenetics of aspirin resistance: a comprehensive systematic review.Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart diseaseInterindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the WoPharmacogenetics and stroke.Pharmacogenetics of cardiovascular drug therapy.Local sustained delivery of acetylsalicylic acid via hybrid stent with biodegradable nanofibers reduces adhesion of blood cells and promotes reendothelialization of the denuded artery.Functional testing methods for the antiplatelet effects of aspirin.Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.The pharmacogenetics of antiplatelet agents: towards personalized therapy?Gene-drug interaction in strokeClinical consequences of aspirin and clopidogrel resistance: an overview.Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists.The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis.The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).Antiplatelet therapy: current strategies and future trends.Aspirin-resistance frequency: a prospective study in 280 healthy Turkish volunteers.Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients.Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.Obesity and Altered Aspirin Pharmacology.Relationship between endothelial functions and acetylsalicylic acid resistance in newly diagnosed hypertensive patients.New single nucleotide polymorphisms associated with differences in platelets reactivity in patients with type 2 diabetes treated with acetylsalicylic acid: genome-wide association approach and pooled DNA strategy.
P2860
Q26801867-1B496DA1-A237-47FE-8D4A-97C39F7B293CQ26860958-49C3B2DB-95DC-4E92-827A-400B643BF451Q27010236-D4B1C791-2683-4062-B401-9C019A7BE63BQ28192298-D69EEAAE-C46F-4904-A2B8-8F01A9DE1BF2Q28196714-74DF2ACE-D7DC-4FF4-A64A-F186DC355EFCQ28200610-114515BE-980F-4922-AF09-871ADC593AEAQ28211940-A657750B-46A8-44D6-9FB7-1E8C2332802EQ28218351-0A8D2F2A-3F22-4931-AF93-CBBECFB68E7DQ33869492-2884B53B-B0F5-474C-9A72-7D9B2247EB2CQ34430932-353B08BE-4938-42DD-A22E-BA050BA17620Q34974280-D0D2A1DA-1C8E-4FBE-B2F7-50FD1807DA69Q35120350-10260DA0-4B39-4812-8F84-B465286BE3C2Q36441528-16050400-C7FA-484C-A229-0415F8497F73Q36769860-1742D3B6-876C-40FF-BB64-07F1FAF86C47Q36897349-55B531C2-797C-4738-A8FE-729183744D0FQ36989841-30F1B839-A74D-463A-B716-552098032969Q37051838-87BC65D0-6167-452F-A569-46FFC7678940Q37089560-DEB51AA7-9B66-4254-9BC9-D5B19305E004Q37145122-99430FD1-304A-4BCA-AF08-B607E332F774Q37248584-02E422DA-DB8A-468A-AE0A-9A2FD1AEC4FFQ37378896-B23F02C1-372D-4B22-9519-BDB5761013AAQ37425335-171553C7-2488-4531-A897-B9C4CE2A2EC3Q37430401-BC059CCC-B3AE-4774-8D66-772DC12CCD6AQ37464405-F6BC8763-945C-4FF1-8A81-E664F38ADC31Q37841562-DFC1702B-82B4-4FE7-AAF0-8CE172C06549Q37882712-46DD8782-CA7B-48EB-9559-4FD42FE0BD65Q37913976-A1AE2EAB-E75C-400E-A88F-1ADB286BC9DCQ37963892-75CEE25C-454B-41BC-9906-B359CACA5FBCQ38083817-509E49AA-60DF-4078-B86B-36A9DCCB9B80Q38117748-AF0D5D6F-1BDB-47CC-AA11-E24994EEA1B6Q38120047-0B2A4869-5B2B-495D-976C-56DD4F168A19Q38750444-3314BDDD-7F72-464A-AB0C-B21C0EA0715AQ40329892-574D12B0-6440-4A97-B041-F6A2EF79C0AAQ46832244-B6B7C9F5-28E2-4230-965D-C8AC17DD3ADCQ46931466-C6028BFF-7247-49A3-B4EB-2882ECB80CC2Q47910448-A837052F-1FE6-4CCA-937D-7EC5F1EE2489Q48302820-5CDF8DD2-24FC-4409-83AD-6B40F3585E4BQ53103471-082AB58F-CCB0-401C-BD85-B20DF5556946Q55056757-36714478-6D5E-4D1C-94AA-97B62DA07ABF
P2860
Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Biological assessment of aspir ...... s response or aspirin failure?
@ast
Biological assessment of aspir ...... s response or aspirin failure?
@en
Biological assessment of aspir ...... s response or aspirin failure?
@nl
type
label
Biological assessment of aspir ...... s response or aspirin failure?
@ast
Biological assessment of aspir ...... s response or aspirin failure?
@en
Biological assessment of aspir ...... s response or aspirin failure?
@nl
prefLabel
Biological assessment of aspir ...... s response or aspirin failure?
@ast
Biological assessment of aspir ...... s response or aspirin failure?
@en
Biological assessment of aspir ...... s response or aspirin failure?
@nl
P2093
P1433
P1476
Biological assessment of aspir ...... s response or aspirin failure?
@en
P2093
Carmen Acuña
Javier Corral
Jose A Guerrero
Jose Rivera
Rocio Gonzalez-Conejero
Vincente Vicente
P304
P356
10.1161/01.STR.0000151362.65339.F9
P407
P577
2005-02-01T00:00:00Z